It was previously reported that VSTM2L was expressed at a low level and predicted poor prognosis in gastric cancer and rectal cancer (Hu et al., 2018; Liu et al., 2021), which was confirmed by our observations in STAD. This evidence concerns the gene VSTM2L and rectal cancer.